SABS (SAB Biotherapeutics) 12-1 Month Momentum % : -59.24% (As of Dec. 14, 2024)

View and export this data going back to 2021. Start your Free Trial

What is SAB Biotherapeutics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-14), SAB Biotherapeutics's 12-1 Month Momentum % is -59.24%.

The industry rank for SAB Biotherapeutics's 12-1 Month Momentum % or its related term are showing as below:

SABS's 12-1 Month Momentum % is ranked worse than
82.93% of 1447 companies
in the Biotechnology industry
Industry Median: -15.46 vs SABS: -59.24

Competitive Comparison of SAB Biotherapeutics's 12-1 Month Momentum %

For the Biotechnology subindustry, SAB Biotherapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SAB Biotherapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where SAB Biotherapeutics's 12-1 Month Momentum % falls into.

SAB Biotherapeutics (NAS:SABS) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SAB Biotherapeutics (NAS:SABS) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

SAB Biotherapeutics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of SAB Biotherapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

SAB Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SAB Biotherapeutics Inc (NAS:SABS) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140

Website

https://www.sab.bio

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Executives

Eddie Joe Sullivan	director, 10 percent owner, officer: Chief Executive Officer	2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Michael King	officer: CHIEF FINANCIAL OFFICER	2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Samuel J Reich	director, officer: Executive Chairman	ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Sessa Capital Im, L.p.	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Andrew Moin	director	2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Sessa Capital (master), L.p.	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Erick Lucera	director	138 THISTLE ROAD, NORTH ANDOVER MA 08145
David Charles Link	director	2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Christine E Hamilton	director, 10 percent owner	225 S MAIN AVE, P O BOX 5000, SIOUX FALLS SD 57117
Scott Giberson	director	2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Alexandra Kropotova	officer: Chief Medical Officer	RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Jeffrey G Spragens	director	4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137